Brainomix Welcomes Khush F. Mehta As New Chair to Enhance Global Growth Strategies

Brainomix's New Leadership: A Vision for Global Growth

In a significant move that underlines its commitment to expanding its global footprint in innovative healthcare solutions, Brainomix has appointed Khush F. Mehta as the new Chair of the Board. This change in stewardship marks not just a new chapter for the company, but also a well-considered strategy to bolster its leadership role in the realm of AI-powered imaging solutions, particularly in the fields of stroke and lung fibrosis.

Khush F. Mehta, whose extensive background encompasses over two decades of pivotal leadership roles in the healthcare sector, succeeds Professor Jacqueline ('Jackie') Hunter CBE, who adeptly guided the company through its formative years. During her five-year tenure, under her leadership, Brainomix doubled in size, secured a substantial presence in the market, and achieved critical milestones in technology adoption. Now, amidst these accomplishments, Mehta steps in to leverage the company’s achievements and direct its growth into new territories.

Mehta previously served as the Chairman at Arterys, a frontrunner in the application of AI within medical imaging, which was acquired by Tempus AI in 2022. His varied experiences include serving as Chief Strategy Officer at Siemens Healthcare, handling its operations across the Asia Pacific region, and holding influential roles in both the United States and Germany. With an impressive academic background — an MBA from Yale School of Management and a Master’s in Commerce and Financial Management from Sydenham College, Mumbai — Mehta brings a wealth of strategic insight to his new position.

Headquartered in the United States, Mehta’s immediate focus will be to foster Brainomix's ongoing efforts toward internationalization. This endeavor is particularly timely as the company recently secured a significant £14M ($18M) Series C investment, which will serve as a catalyst for accelerating its commercial expansion efforts in both U.S. and international markets. The investment aligns strategically with the recent FDA clearance for a novel feature in its Brainomix 360 platform, a pivotal development that solidifies its status as a leader in AI imaging technologies.

According to Dr. Michalis Papadakis, CEO and Co-Founder of Brainomix, Mehta's extensive experiences and deep understanding of healthcare AI position him uniquely to guide the company through this crucial phase. He expressed confidence that Mehta’s leadership will crucially impact the company’s mission to enhance patient outcomes across multiple geographies.

Mehta acknowledged the prestige of his new role, remarking, “Brainomix has developed one of the most clinically impactful AI platforms, demonstrating significant positive changes in stroke care. I am honored to guide the company into its next chapter while exploring expansion into new regions and therapeutic applications.” His optimism echoes the sentiments of the outgoing Chair, Jackie Hunter, who oversaw the dramatic transformation of Brainomix from a fledgling start-up to a robust scale-up.

In her parting remarks, Hunter praised the company's tremendous achievements and expressed her excitement for Brainomix's future endeavors under Mehta’s guidance. She noted substantial clinical adoption of the Brainomix 360 Stroke tool and highlighted the firm’s strategic growth into Life Sciences with partnerships forged with leading global pharmaceutical companies.

As Brainomix positions itself for sustainable success in the healthcare AI sector, the departure of Andrew Barker, its first Chair and crucial guide during its formative years, signals a turning point, blending legacy with fresh leadership. The company now sets forth into a promising future, one that Mehta is determined to navigate with a focus on innovation and global presence.

About Brainomix

Brainomix specializes in developing AI-driven software solutions intended to optimize precision medicine, particularly for stroke and lung fibrosis treatments. After its inception as a spinout from the University of Oxford, it has evolved into a commercially viable entity with offices in the United Kingdom, Ireland, and the United States, serving patients in over 20 countries worldwide. The internationally acclaimed Brainomix 360 stroke platform serves healthcare professionals by providing comprehensive imaging solutions aimed at enhancing treatment rates and improving patient independence, addressing a critical need in timely and effective stroke care.

To further explore the groundbreaking innovations of Brainomix, visit www.brainomix.com and follow the company on Twitter, LinkedIn, and Facebook for the latest updates.